HumanX Takes AI's Biggest Stage to Europe with Amsterdam Expansion
6.10.2025 10:00:00 EEST | Business Wire | Press release
HumanX, the world’s leading AI event, is officially coming to Europe. Built by the team behind Money20/20, Shoptalk, and HLTH, the organization announced today the launch of HumanX EMEA, a new global gathering taking place September 22-24, 2026, at The RAI in Amsterdam.
Already established as the premier ecosystem enabling enterprise AI strategy, implementation, and cross-sector collaboration in the United States, HumanX now brings its proven platform to Europe at a time of historic momentum for the region’s AI ecosystem. The expansion comes on the heels of HumanX’s rapid growth in the U.S., where its next event will draw over 6,000 attendees, 350 speakers, 400 vendors, and more than 300 media from across the globe.
HumanX EMEA connects Europe's AI ecosystem with global leaders, bringing together 2,500+ senior practitioners, partners, and 200+ media alongside speakers from the U.S., Asia, and Europe. The event focuses on responsible, high-impact AI adoption - not as an imported American conference, but as a bridge uniting Europe's thriving AI community with its global counterparts.
“Europe is at a pivotal moment in AI, and it deserves a world-class platform that reflects its growing influence in shaping the future of artificial intelligence,” said Stefan Weitz, CEO of HumanX. “European companies are incredibly innovative, but they need access to the same caliber of strategic insights and proven playbooks that are accelerating AI adoption globally. HumanX is built to meet this moment: a platform for solutions, partnerships, and action that helps leaders cut through barriers, align global momentum with European strengths, and drive AI forward in a way that’s responsible, ambitious, and uniquely European.”
Today, HumanX EMEA also announces its first 50 speakers, including Clay Bavor, Co-founder at Sierra and former Google AR/VR leader; May Habib, co-founder & CEO at Writer; and Douwe Kiela, Co-founder & CEO of Contextual. The lineup features executives from over 15 unicorns, including Quantexa, Owkin, and Decagon, as well as leading venture capital firms Lightspeed, Renegade Partners and Radical Ventures.
Amsterdam was chosen as the European hub for its strategic position as a gateway between Europe, the Middle East, and global markets, combined with the Netherlands' progressive approach to AI governance and robust multilingual tech infrastructure.
"We welcome HumanX and its global community to The Netherlands. Hosting the EMEA event in Amsterdam will facilitate collaboration and knowledge-sharing, and help our ecosystem to connect and thrive in this fast-changing field," said Constantijn van Oranje, special envoy of Techleap, which has also become an event supporter.
“We are thrilled to welcome HumanX to Amsterdam, a city that thrives on creativity and connection. Artificial Intelligence is not just a technology; it is a force that will shape how we live, work, and solve global challenges,” said Maurits van der Sluis, Member of the Board RAI Amsterdam. “By bringing the world’s AI community together, HumanX helps unlock new ideas and inspires collaboration that can drive a better future for Amsterdam, the Netherlands, and beyond.”
In the lead-up to the event, HumanX will host multiple events, dinners, and gatherings across Europe to build community and foster connections.
HumanX EMEA 2026will open registration in early 2026, with further speaker and partner announcements rolling out throughout the year.
Learn more about HumanX EMEA 2026 here
About HumanX
HumanX is the premier AI strategy summit for global executives, investors, and innovators. Built by the team behind Money20/20, Shoptalk, and HLTH, it convenes senior decision-makers to exchange actionable insights, forge high-value partnerships, and accelerate enterprise adoption of AI. With no pay-to-play agenda and a focus on real business outcomes, HumanX is where vision translates into measurable value.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251006576249/en/
Contacts
Barry Salmon
Head of Media, HumanX
barry@humanx.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom